Skip to main content

Recombinant human FGFR4 (mutated V550E) protein (Active) is a Human Fragment protein, in the 460 to 802 aa range, expressed in Baculovirus infected Sf9, with >75% purity and suitable for SDS-PAGE, FuncS.

Be the first to review this product! Submit a review

Images

Functional Studies - Recombinant human FGFR4 (mutated V550E) protein (Active) (AB268576), expandable thumbnail
  • SDS-PAGE - Recombinant human FGFR4 (mutated V550E) protein (Active) (AB268576), expandable thumbnail

Key facts

Purity
>75% SDS-PAGE
Expression system
Baculovirus infected Sf9 cells
Tags
GST tag N-Terminus
Applications
SDS-PAGE, FuncS
Biologically active
Yes

Reactivity data

Application
SDS-PAGE
Reactivity
Reacts
Dilution info
-
Notes

-

Application
FuncS
Reactivity
Reacts
Dilution info
-
Notes

-

Target data

Function

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.

Alternative names

Recommended products

Recombinant human FGFR4 (mutated V550E) protein (Active) is a Human Fragment protein, in the 460 to 802 aa range, expressed in Baculovirus infected Sf9, with >75% purity and suitable for SDS-PAGE, FuncS.

Key facts

Purity
>75% SDS-PAGE
Expression system
Baculovirus infected Sf9 cells
Applications
SDS-PAGE, FuncS
Biological activity
The specific activity of ab268576 was 85 nmol/min/mg in a kinase assay using Poly (4:1 Glu, Tyr) synthetic peptide as substrate.
Accession
P22455-1
Animal free
No
Species
Human
Concentration
Loading...
Storage buffer

pH: 7.5
Constituents: 25% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, 0.79% Tris HCl, 0.31% Glutathione, 0.004% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.003% EDTA, 0.002% PMSF

Sequence info

Amino acid sequence

Accession
P22455
Protein length
Fragment
Amino acids
460 to 802
Nature
Recombinant
Tags
GST tag N-Terminus

Specifications

Form
Liquid
Additional notes

Affinity purified.

General info

Function

Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.

Sequence similarities

Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.

Post-translational modifications

N-glycosylated. Full maturation of the glycan chains in the Golgi is essential for high affinity interaction with FGF19.

Subcellular localisation
Endosome

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

This product is an active protein and may elicit a biological response in vivo, handle with caution.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

FGFR4 or fibroblast growth factor receptor 4 is a receptor tyrosine kinase weighing approximately 110 kDa. This protein plays a role in cellular processes by binding to fibroblast growth factors. FGFR4 is expressed in many tissues including muscle liver and the developing epidermis. It is known by alternate names like CD334 or FRFR4. This receptor's activation leads to receptor dimerization and autophosphorylation triggering downstream signaling pathways that affect cell proliferation differentiation and migration.

Biological function summary

FGFR4 influences various developmental and metabolic processes. It is important in limb and skeletal development epithelial cell morphogenesis and muscle fiber regeneration. FGFR4 often partners with heparan sulfate proteoglycans to form a signaling complex which defines the specificity and regulation of fibroblast growth factor signaling. The receptor's interaction with other proteins like FRFR4 and 5b5 further modulates its biological activity.

Pathways

FGFR4 participates in the MAPK and PI3K-Akt signaling pathways both important for regulating cell survival and growth. These pathways allow FGFR4 to connect with several other proteins such as FGFR1 and BLU-554. FGFR4's activation within these pathways helps determine cellular responses to hormonal and mitogenic signals further influencing tissue homeostasis and repair mechanisms.

Associated diseases and disorders

FGFR4 is linked to certain cancers including hepatocellular carcinoma and colorectal cancer notable in cell lines like HCT116 and others. Overexpression or mutations in FGFR4 can drive tumor progression promoting uncontrolled growth and metastasis. FGFR4's relation to other key proteins such as FRAF and 19h3 highlights its role in pathogenesis making it a potential target for therapeutic interventions. Studies involving FGFR4 ELISA kits enhance understanding of its role in disease development and progression.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

  • Functional Studies - Recombinant human FGFR4 (mutated V550E) protein (Active) (ab268576), expandable thumbnail

    Functional Studies - Recombinant human FGFR4 (mutated V550E) protein (Active) (ab268576)

    The specific activity of ab268576 was 85 nmol/min/mg in a kinase assay using Poly (4:1 Glu, Tyr) synthetic peptide as substrate.

  • SDS-PAGE - Recombinant human FGFR4 (mutated V550E) protein (Active) (ab268576), expandable thumbnail

    SDS-PAGE - Recombinant human FGFR4 (mutated V550E) protein (Active) (ab268576)

    SDS-PAGE analysis of ab268576.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com